THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN PACLITAXEL COMBINATION CHEMOTHERAPY

Presence of functional immune system is critical for any attempt aimed at improving survival of breast cancer patients by strategies based on immune system manipulation. We evaluated by flow cytometry the phenotype of peripheral blood leukocyte of 43 breast cancer patients. In 11 patients, the pheno...

Full description

Saved in:
Bibliographic Details
Published in:Immunopharmacology and immunotoxicology 2001-01, Vol.23 (2), p.163-173
Main Authors: Melichar, Bohuslav, Toušková, Miroslava, Dvo ák, Josef, Jandík, Pavel, Kopecký, Otakar
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, CD - metabolism
Antigens, Differentiation, T-Lymphocyte - metabolism
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Breast Neoplasms - immunology
Case-Control Studies
CD28 Antigens - metabolism
CD3 Complex - metabolism
CD4-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - immunology
doxorubicin
Doxorubicin - administration & dosage
Female
Gynecology. Andrology. Obstetrics
HLA-DR Antigens - metabolism
Humans
Immunophenotyping
Lectins, C-Type
Leukocytes - immunology
Lipopolysaccharide Receptors - metabolism
Lymphocyte Subsets - immunology
Mammary gland diseases
Medical sciences
Middle Aged
paclitaxel
Paclitaxel - administration & dosage
Receptors, IgG - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Presence of functional immune system is critical for any attempt aimed at improving survival of breast cancer patients by strategies based on immune system manipulation. We evaluated by flow cytometry the phenotype of peripheral blood leukocyte of 43 breast cancer patients. In 11 patients, the phenotype was evaluated before and during the chemotherapy by combination of doxorubicin and paclitaxel (AT). Compared with controls breast cancer patients had significantly higher relative and absolute numbers of CD3−HLADR+, CD3−CD69+ and CD14+CD16−, and significantly lower percentages of CD3− and CD8−CD28+ cells. After one cycle of AT, the absolute numbers of CD3+, CD3−CD4−, CD3+CD8+ and CD8−CD28+ cells increased significantly. Present data show a presence of T-cell activation in breast cancer patients. Administration of AT may lead to an increase in functional T-cells in peripheral blood, indicating a potential for combining chemotherapy with immunotherapy in the treatment of breast cancer patients.
ISSN:0892-3973
1532-2513
DOI:10.1081/IPH-100103857